Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration
Objective The Canadian Real-world Evidence for Value in Cancer (CanREValue) Collaboration was established in response to growing interest in using real-world evidence (RWE) to support health technology assessment (HTA). CanREValue has developed a framework to generate and use RWE to inform cancer dr...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-05-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/15/5/e096286.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849689477037948928 |
|---|---|
| author | Stuart Peacock Avram Denburg Petros Pechlivanoglou Wanrudee Isaranuwatchai Claire de Oliveira Yvonne Bombard Scott Gavura Jeffrey Hoch Rebecca E Mercer Wei Fang Dai Jaclyn Beca Mina Tadrous Carole Chambers Maureen Trudeau Craig C Earle Kelvin Kar-Wing Chan Winson Y Cheung Pam Takhar William K Evans Caroline Muñoz Erica Craig Marc Geirnaert Tarry Ahuja Riaz Alvi |
| author_facet | Stuart Peacock Avram Denburg Petros Pechlivanoglou Wanrudee Isaranuwatchai Claire de Oliveira Yvonne Bombard Scott Gavura Jeffrey Hoch Rebecca E Mercer Wei Fang Dai Jaclyn Beca Mina Tadrous Carole Chambers Maureen Trudeau Craig C Earle Kelvin Kar-Wing Chan Winson Y Cheung Pam Takhar William K Evans Caroline Muñoz Erica Craig Marc Geirnaert Tarry Ahuja Riaz Alvi |
| author_sort | Stuart Peacock |
| collection | DOAJ |
| description | Objective The Canadian Real-world Evidence for Value in Cancer (CanREValue) Collaboration was established in response to growing interest in using real-world evidence (RWE) to support health technology assessment (HTA). CanREValue has developed a framework to generate and use RWE to inform cancer drug funding decisions.Design and participants The RWE framework was developed using a multistage, multistakeholder approach. First, an environmental scan and qualitative study were conducted to understand the current state and key stakeholder perspectives on RWE. Next, five formal working groups (WGs) were established consisting of stakeholders with cancer drug funding expertise including clinicians, patients, methodologists, payers, regulatory decision-makers and data analysts. Through stakeholder consultations, including modified Delphi exercises and workshops, each WG developed specific framework components and identified facilitators and barriers that may impact the uptake of RWE.Setting The CanREValue Collaboration consisted of membership and participation from stakeholders and expertise from across Canada. Central research operations were managed from Toronto, Ontario, Canada.Outcomes Development of an RWE framework reflective of the needs and perspectives of stakeholders directly involved and/or impacted by cancer drug funding decisions across Canada.Results Through an iterative process, a comprehensive RWE framework was developed that outlined the end-to-end processes necessary for the generation and use of RWE for HTA reassessment in Canada. The framework consists of four phases that uses various tools, templates and processes, which can be applied as a whole or in part. A diverse range of stakeholders and expertise is involved in the decision-making of each phase of the process: Phase I: identification, selection and prioritisation of RWE questions; phase II: initiating and planning the RWE study; phase III: conducting the RWE study and phase IV: conducting reassessment.Conclusions As the cancer drug funding landscape continues to evolve, the need for RWE to support evidence-based policy reform, pricing and reallocation of funding from low to high value settings is crucial. We have developed a framework that is adaptable and responsive to the changing landscape. The tools, templates and processes within the framework can be applied by various stakeholder groups in whole or in part to support cancer drug funding decision-making in Canada and can be adapted for use in other jurisdictions. |
| format | Article |
| id | doaj-art-2a95268eae944ff888f84a50f434ab3c |
| institution | DOAJ |
| issn | 2044-6055 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj-art-2a95268eae944ff888f84a50f434ab3c2025-08-20T03:21:38ZengBMJ Publishing GroupBMJ Open2044-60552025-05-0115510.1136/bmjopen-2024-096286Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaborationStuart Peacock0Avram Denburg1Petros Pechlivanoglou2Wanrudee Isaranuwatchai3Claire de Oliveira4Yvonne Bombard5Scott Gavura6Jeffrey Hoch7Rebecca E Mercer8Wei Fang Dai9Jaclyn Beca10Mina Tadrous11Carole Chambers12Maureen Trudeau13Craig C Earle14Kelvin Kar-Wing Chan15Winson Y Cheung16Pam Takhar17William K Evans18Caroline Muñoz19Erica Craig20Marc Geirnaert21Tarry Ahuja22Riaz Alvi23Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, CanadaChild Health and Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, CanadaInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, CanadaHealth Intervention and Technology Assessment Program, Mueang Nonthaburi, Nonthaburi, ThailandInstitute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, CanadaGenomics Health Services Research Program, Li Ka Shing Knowledge Institute, St. Michael`s Hospital, Unity Health Toronto, Toronto, Ontario, Canada4 Department of Oncology, Provincial Drug Reimbursement Programs, Cancer Care Ontario, Toronto, Ontario, CanadaDepartment of Public Health Sciences, University of California, Sacramento, California, USA3 Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada3 Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada3 Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, CanadaICES, Toronto, Ontario, CanadaAlberta Health Services, Calgary, Alberta, Canada7University of Toronto, Toronto, Ontario, Canada3 Institute for Clincal Evaluative Sciences, Toronto, Ontario, CanadaOdette Cancer Centre, Sunnybrook Health Sciences Centre, Division of Hematology and Oncology, Department of Medicine, University of Toronto, Toronto, Ontario, CanadaDepartment of Community Health Sciences, University of Calgary, Calgary, Alberta, CanadaCanadian Centre for Applied Research in Cancer Control, Toronto, Ontario, CanadaDepartment of Oncology, McMaster University, Hamilton, Ontario, CanadaCanadian Centre for Applied Research in Cancer Control, Toronto, Ontario, CanadaNew Brunswick Cancer Network, Fredericton, New Brunswick, CanadaCancer Care Manitoba, Winnipeg, Manitoba, CanadaCanada’s Drug Agency, Ottawa, Ontario, CanadaSaskatchewan Cancer Agency, Saskatoon, Saskatchewan, CanadaObjective The Canadian Real-world Evidence for Value in Cancer (CanREValue) Collaboration was established in response to growing interest in using real-world evidence (RWE) to support health technology assessment (HTA). CanREValue has developed a framework to generate and use RWE to inform cancer drug funding decisions.Design and participants The RWE framework was developed using a multistage, multistakeholder approach. First, an environmental scan and qualitative study were conducted to understand the current state and key stakeholder perspectives on RWE. Next, five formal working groups (WGs) were established consisting of stakeholders with cancer drug funding expertise including clinicians, patients, methodologists, payers, regulatory decision-makers and data analysts. Through stakeholder consultations, including modified Delphi exercises and workshops, each WG developed specific framework components and identified facilitators and barriers that may impact the uptake of RWE.Setting The CanREValue Collaboration consisted of membership and participation from stakeholders and expertise from across Canada. Central research operations were managed from Toronto, Ontario, Canada.Outcomes Development of an RWE framework reflective of the needs and perspectives of stakeholders directly involved and/or impacted by cancer drug funding decisions across Canada.Results Through an iterative process, a comprehensive RWE framework was developed that outlined the end-to-end processes necessary for the generation and use of RWE for HTA reassessment in Canada. The framework consists of four phases that uses various tools, templates and processes, which can be applied as a whole or in part. A diverse range of stakeholders and expertise is involved in the decision-making of each phase of the process: Phase I: identification, selection and prioritisation of RWE questions; phase II: initiating and planning the RWE study; phase III: conducting the RWE study and phase IV: conducting reassessment.Conclusions As the cancer drug funding landscape continues to evolve, the need for RWE to support evidence-based policy reform, pricing and reallocation of funding from low to high value settings is crucial. We have developed a framework that is adaptable and responsive to the changing landscape. The tools, templates and processes within the framework can be applied by various stakeholder groups in whole or in part to support cancer drug funding decision-making in Canada and can be adapted for use in other jurisdictions.https://bmjopen.bmj.com/content/15/5/e096286.full |
| spellingShingle | Stuart Peacock Avram Denburg Petros Pechlivanoglou Wanrudee Isaranuwatchai Claire de Oliveira Yvonne Bombard Scott Gavura Jeffrey Hoch Rebecca E Mercer Wei Fang Dai Jaclyn Beca Mina Tadrous Carole Chambers Maureen Trudeau Craig C Earle Kelvin Kar-Wing Chan Winson Y Cheung Pam Takhar William K Evans Caroline Muñoz Erica Craig Marc Geirnaert Tarry Ahuja Riaz Alvi Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration BMJ Open |
| title | Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration |
| title_full | Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration |
| title_fullStr | Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration |
| title_full_unstemmed | Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration |
| title_short | Development of a framework on the incorporation of real-world evidence (RWE) into cancer drug funding decisions in Canada: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration |
| title_sort | development of a framework on the incorporation of real world evidence rwe into cancer drug funding decisions in canada the canadian real world evidence for value of cancer drugs canrevalue collaboration |
| url | https://bmjopen.bmj.com/content/15/5/e096286.full |
| work_keys_str_mv | AT stuartpeacock developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT avramdenburg developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT petrospechlivanoglou developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT wanrudeeisaranuwatchai developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT clairedeoliveira developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT yvonnebombard developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT scottgavura developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT jeffreyhoch developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT rebeccaemercer developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT weifangdai developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT jaclynbeca developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT minatadrous developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT carolechambers developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT maureentrudeau developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT craigcearle developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT kelvinkarwingchan developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT winsonycheung developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT pamtakhar developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT williamkevans developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT carolinemunoz developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT ericacraig developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT marcgeirnaert developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT tarryahuja developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration AT riazalvi developmentofaframeworkontheincorporationofrealworldevidencerweintocancerdrugfundingdecisionsincanadathecanadianrealworldevidenceforvalueofcancerdrugscanrevaluecollaboration |